FIELD: biotechnology.
SUBSTANCE: invention relates to genetic engineering and biotechnology, in particular to the VTvaf17 gene-therapy DNA vector of 3165 bp size and a process for its preparation. Said VTvaf17 DNA vector is intended for genetic modification of animal and human cells and has the nucleotide sequence of SEQ ID NO: 1. Present invention also relates to a strain Escherichia coli SCS110-AF, to a strain Escherichia coli SCS110-AF/VTvaf17 and to methods for preparation thereof. E. coli SCS110-AF strain is intended for resulting VTvaf17 gene-therapy DNA vector or gene-therapy DNA vectors based on it and contains in the chromosome in the gene recA region a linear fragment containing the regulatory element RNA-in of the transposon Tn10. E. coli SCS110-AF/VTvaf17 strain contains VTvaf17 DNA vector gene-therapy and is intended for resulting thereof. Said E. coli SCS110-AF/VTvaf17 strain produced by electroporation of E. coli SCS110-AF strain cells by DNA vector VTvaf17.
EFFECT: invention makes it possible to obtain a DNA vector for genetic modification of animal and human cells.
6 cl, 6 dwg, 10 ex
